Kringle Pharma, Inc. (TYO:4884)

Kringle Pharma Statistics

Total Valuation

Kringle Pharma has a market cap or net worth of JPY 2.79 billion. The enterprise value is 1.20 billion.

Market Cap	2.79B
Enterprise Value	1.20B

Important Dates

The last earnings date was Monday, May 11, 2026.

Earnings Date	May 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Kringle Pharma has 7.40 million shares outstanding. The number of shares has increased by 4.20% in one year.

Current Share Class	7.40M
Shares Outstanding	7.40M
Shares Change (YoY)	+4.20%
Shares Change (QoQ)	+2.24%
Owned by Insiders (%)	5.76%
Owned by Institutions (%)	3.98%
Float	6.02M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	38.19
PB Ratio	2.94
P/TBV Ratio	2.94
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.30
EV / Sales	16.44
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.79

Current Ratio	4.79
Quick Ratio	3.95
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -72.02% and return on invested capital (ROIC) is -44.67%.

Return on Equity (ROE)	-72.02%
Return on Assets (ROA)	-26.68%
Return on Invested Capital (ROIC)	-44.67%
Return on Capital Employed (ROCE)	-57.86%
Weighted Average Cost of Capital (WACC)	6.16%
Revenue Per Employee	4.29M
Profits Per Employee	-54.12M
Employee Count	17
Asset Turnover	0.03
Inventory Turnover	n/a

Taxes

In the past 12 months, Kringle Pharma has paid 2.00 million in taxes.

Income Tax	2.00M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -60.14% in the last 52 weeks. The beta is 0.35, so Kringle Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.35
52-Week Price Change	-60.14%
50-Day Moving Average	442.32
200-Day Moving Average	432.25
Relative Strength Index (RSI)	29.78
Average Volume (20 Days)	228,745

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kringle Pharma had revenue of JPY 73.00 million and -920.00 million in losses. Loss per share was -130.47.

Revenue	73.00M
Gross Profit	73.00M
Operating Income	-913.00M
Pretax Income	-918.00M
Net Income	-920.00M
EBITDA	n/a
EBIT	-913.00M
Loss Per Share	-130.47

Balance Sheet

The company has 1.59 billion in cash and n/a in debt, with a net cash position of 1.59 billion or 214.74 per share.

Cash & Cash Equivalents	1.59B
Total Debt	n/a
Net Cash	1.59B
Net Cash Per Share	214.74
Equity (Book Value)	947.00M
Book Value Per Share	128.06
Working Capital	1.55B

Cash Flow

Operating Cash Flow	-520.00M
Capital Expenditures	n/a
Depreciation & Amortization	n/a
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	100.00%
Operating Margin	-1,250.68%
Pretax Margin	-1,257.53%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kringle Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.20%
Shareholder Yield	-4.20%
Earnings Yield	-33.00%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Kringle Pharma has an Altman Z-Score of 0.16 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.16
Piotroski F-Score	2